Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Grants and contracts	$ 3,570,710	$ 8,790,209	$ 15,331,567
Operating expenses:
Research and development	22,501,805	22,788,887	16,141,040
General and administrative	11,115,511	11,106,493	9,927,725
Total operating expenses	33,617,316	33,895,380	26,068,765
Loss from operations	(30,046,606)	(25,105,171)	(10,737,198)
Other income (expense):
Interest and other income (expense)	(70,015)	53,659	77,110
Change in value of warrant liability	7,701,981	19,821,787	(16,011,769)
Total other income (expense)	7,631,966	19,875,446	(15,934,659)
Net loss	(22,414,640)	(5,229,725)	(26,671,857)
Net loss attributable to noncontrolling interests	4,180,498	1,216,055	305,812
Net loss attributable to Cleveland BioLabs, Inc.	$ (18,234,142)	$ (4,013,670)	$ (26,366,045)
Net loss available to common stockholders per share of common stock, basic and diluted (in Dollars per share)	$ (0.49)	$ (0.12)	$ (1.01)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in Shares)	37,388,847	32,561,743	26,184,773